Related Experiment Video
Updated: Jan 3, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Risk factor, monitoring, and treatment for snakebite induced coagulopathy: a multicenter retrospective study
Yong Jun Jeon1, Jong Wan Kim2, SungGil Park2
1Department of Surgery, Chinjujeil Hospital, Jinju, Korea.
Insights
Lower cholesterol levels may indicate a higher risk of disseminated intravascular coagulation (DIC) after snakebite. Coagulopathy monitoring is essential for 4-5 days post-bite, as standard treatments may not benefit patients without bleeding.
Area of Science:
- Toxicology
- Hematology
- Clinical Medicine
Background:
- Snakebite envenomation can lead to coagulopathy, a complication distinct from disseminated intravascular coagulation (DIC) from other causes.
- The optimal treatment for snakebite-associated coagulopathy remains a subject of debate.
Purpose of the Study:
- To investigate the clinical features and outcomes of snakebite-associated coagulopathy.
- To identify risk factors for overt DIC following snakebite.
- To evaluate the effectiveness of current treatment strategies.
Main Methods:
- Retrospective review of medical records for patients hospitalized due to snakebite between January 2006 and September 2018.
- Analysis of patient demographics, clinical presentations, laboratory results, and treatment interventions.
- Application of the International Society of Thrombosis and Hemostasis scoring system to diagnose overt DIC.
Main Results:
- Of 226 hospitalized patients, 21 developed overt DIC. Initial low cholesterol levels were associated with overt DIC development.
- Prolonged International Normalized Ratio (INR) was observed up to 4-5 days post-bite.
- High-dose antivenom and blood product transfusions (fresh frozen plasma, cryoprecipitate) did not shorten INR duration or hospital stay in non-bleeding DIC patients.
Conclusions:
- Low initial cholesterol may be a risk factor for overt DIC post-snakebite.
- Continuous coagulopathy assessment for at least 4-5 days is crucial, even in asymptomatic patients.
- Aggressive antivenom and transfusion strategies may not be beneficial for coagulopathic patients without active bleeding.
Background:
Snakebite can cause various complications, including coagulopathy. The clinical features of snakebite-associated coagulopathy differ from those of disseminated intravascular coagulation (DIC) caused by other diseases and its treatment is controversial.
Methods:
We retrospectively reviewed the medical records of patients hospitalized for snakebite between January 2006 and September 2018.
Results:
A total of 226 patients were hospitalized due to snakebite. Their median hospital stay was 4.0 days (interquartile range, 2.0 to 7.0 days). Five patients arrived at hospital with shock and one patient died. Twenty-one patients had overt DIC according to the International Society of Thrombosis and Hemostasis scoring system. Two patients developed major bleeding complications. Initial lower cholesterol level at presentation was associated with the development of overt DIC. International normalization ratio (INR) exceeding the laboratory's measurement limit was recorded as late as 4 to 5 days after the bite. Higher antivenom doses (≥18,000 units) and transfusion of fresh frozen plasma (FFP) or cryoprecipitate did not affect prolonged INR duration or hospital stay in the overt DIC patients without bleeding.
Conclusions:
Initial lower cholesterol level may be a risk factor for overt DIC following snakebite. Although patients lack apparent symptoms, the risk of coagulopathy should be assessed for at least 4 to 5 days following snakebite. Higher antivenom doses and transfusion of FFP or cryoprecipitate may be unbeneficial for coagulopathic patients without bleeding.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

